Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
Provided By GlobeNewswire
Last update: Jan 9, 2025
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD)
Read more at globenewswire.comNASDAQ:ABOS (4/23/2025, 11:36:42 AM)
0.9629
-0.02 (-1.74%)
Find more stocks in the Stock Screener
